The burden and determinants of complications and comorbidities in contemporary youth-onset diabetes are unknown.
CONCLUSIONS AND RELEVANCE Among teenagers and young adults who had been diagnosed with diabetes during childhood or adolescence, the prevalence of complications and comorbidities was higher among those with type 2 diabetes compared with type 1, but frequent in both groups. These findings support early monitoring of youth with diabetes for development of complications.
States. 3 These recent epidemiologic trends in type 1 and type 2 diabetes diagnosed in young individuals raise the question of whether the pattern of complications differs by diabetes type at similar ages and diabetes duration. Recent studies have reported higher prevalence of some [5] [6] [7] but not all 8 complications in children and adolescents with type 2 diabetes compared with those with type 1. Reasons for discrepancies across previous studies include population differences, relatively small sample sizes, variable length of duration of diabetes at outcome assessment, variable ages, and reliance on routine clinical or administrative records to document outcomes. Preliminary findings have suggested that there is a higher prevalence of selected complications and risk factors among adolescents and young adults with type 2 diabetes compared with type 1.
9
Given those findings, this study was designed as an outcomes evaluation to comprehensively estimate the prevalence of multiple diabetes-related complications (retinopathy, neuropathy, and nephropathy) and comorbidities (hypertension and arterial stiffness) by type of diabetes. The a priori hypothesis was that the prevalence of complications and comorbidities would be higher in adolescents and young adults with type 2 diabetes compared with those with type 1. The secondary hypothesis was that the increased prevalence of complications would be reduced, at least in part, by adjustment for longitudinally measured established risk factors, including glycemia (hemoglobin A 1c level), obesity (body mass index [BMI] ; waist-height ratio), and blood pressure (mean arterial pressure).
Methods

Study Population
Children and adolescents with diabetes diagnosed at younger than 20 years were identified from a population-based incidence registry network at 5 US sites (South Carolina; Cincinnati, Ohio, and surrounding counties; Colorado with southwestern Native American sites; Seattle, Washington, and surrounding counties; and Kaiser Permanente, Southern California) by the SEARCH for Diabetes in Youth registry study. 9 Patients received a new diagnosis of type 1 or type 2 diabetes in 2002-2006 or 2008 and were identified from ongoing surveillance of networks of hospitals and other clinical sites. Patients who could be contacted were recruited for a baseline visit (mean of 9.3 months [SD, 6.4] from diagnosis) and, if they completed it, were asked to return for visits at 12, 24, and 60 months to measure risk factors for diabetes complications ( Figure 1) . A subset of participants aged 10 years or older who had at least 5 years of diabetes duration (to increase the likelihood of detection of complications) were recruited for an outcome visit between 2011 and 2015 (mean of 7.9 years [SD, 1.9] from diagnosis), for whom a single prevalent measurement of diabetes-related complications and comorbidities was completed. A flowchart depicting included and excluded participants is shown in Figure 2 . The study was approved by institutional review boards with jurisdiction, and for all participants, the parent, adolescent or young adult, or both provided consent or assent.
Research Visits
Trained personnel administered questionnaires, made measurements, and obtained blood samples. Because race and ethnicity are often related to differing disease outcomes, US census methods 10 were used that provided a series of fixed race and ethnicity categories, as well as an "other" option for the self-report by parent or participant, depending on age. These were further categorized into non-Hispanic white and minority racial/ethnic groups, including Hispanic (regardless of race), non-Hispanic black, American Indian, Asian/Pacific Islander, and other or multiple races/ethnicities. Education and income were self-reported. Body mass index was calculated as weight in kilograms divided by height in meters squared and converted to a z score. 11 Waist circumference
was measured with the natural waist location and was used to calculate the ratio of waist to height. The mean of 3 systolic and diastolic blood pressure levels was obtained with an aneroid manometer after at least 5 minutes of rest. A blood draw occurred after an 8-hour overnight fast, and medications, including short-acting insulin, were withheld the morning of the visit.
Laboratory Measures
Specimens were analyzed for glutamic acid decarboxylase-65 antibodies and insulinoma-associated-2 antibodies at the central laboratory 12 (Northwest Lipid Metabolism and Diabetes Research). Zinc-T8 autoantibody was analyzed at the Eisenbarth Laboratory (University of Colorado). 13 Levels of fasting C-peptide, hemoglobin A 1c , glucose, lipids, creatinine, cystatin C, and urine albumin and creatinine were also measured. 
Type of Diabetes
Outcome Measures
Diabetic Kidney Disease A first-morning urine void at home was brought to the outcome visit by 92% of participants, and if not available (in 8%), a spot sample was used. Diabetic kidney disease was defined as the presence of albuminuria (≥30 μg/mg of creatinine) or estimated glomerular filtration rate less than or equal to 60 mL/min/1.73 m 2 with the CKD-Epi equations with serum creatinine and cystatin C. 16 Only 1 participant was classified as having diabetic kidney disease according to low estimated glomerular filtration rate. Diabetic retinopathy was determined by grading 45°color digital fundus images centered on the disc and macula of both eyes, taken with a nonmydriatic camera (Visucam Pro N; Carl Zeiss Meditech). The Wisconsin Ocular Epidemiology Reading Center graded photos masked to all clinical characteristics. Retinopathy severity was based on the worse eye and categorized as none, minimal nonproliferative, mild to moderate nonproliferative, or proliferative. 17 Diabetic retinopathy was defined as presence of mild, moderate, or proliferative retinal changes. Peripheral neuropathy was assessed with the Michigan Neuropathy Screening Instrument examination and was defined as a score greater than 2.
18,19
Cardiovascular Autonomic Neuropathy Assessment of heart rate variability used the SphygmoCor-Vx device (AtCor Medical). 20 Indices of heart rate variability were derived from the electrocardiographic R-R intervals and included standard deviation of the intervals, root mean square differences of successive intervals, normalized highfrequency power, normalized low-frequency power, and the low-frequency to high-frequency ratio. Cardiovascular autonomic neuropathy was defined as at least 3 of 5 abnormalities 
Statistical Methods
Descriptive analyses calculated the mean (SD) or median (interquartile range [when data were not normally distributed]) for continuous variables and the number and percentage for categorical variables. Variables labeled "current" were from the outcomes visit and those labeled "mean over time" were the mean of all available visits from baseline to the outcomes visit (maximum possible = 5 visits). Hemoglobin A 1c levels (glucose control), BMI levels (overall obesity), and waistheight ratio (central obesity) from all visits were averaged. Mean arterial pressure was calculated as ([2 × diastolic] + systolic)/3 at each visit and averaged.
Prevalence of Outcomes
The prevalence of each outcome was estimated at age 21 years by diabetes type, as well as by type and race/ethnicity, with logistic regression. Absolute differences and 95% CIs were calculated from the age-adjusted prevalence estimates.
Risk Factors and Prevalence Differences
To understand which risk factors were associated with prevalence differences, odds ratios (ORs) and 95% CIs for the associations between diabetes type (type 2 vs 1) and each outcome were computed in sequentially adjusted models. A base model adjusted for age, sex, duration of diabetes, and clinical site. Additional models explored whether adjustment for individual covariates reduced the strength of the associations: race/ ethnicity, hemoglobin A 1c level, BMI, waist-height ratio, and mean arterial pressure averaged over time (except when hypertension was the outcome, in which case mean arterial pressure was not included). A final model explored the changes in the ORs, with adjustment for all risk factors (except BMI, which was highly correlated with waist-height ratio). Model fit was determined with the Hosmer-Lemeshow goodness-of-fit test. Analyses used SAS version 9.4. All analyses used 2-sided P = .05 as statistically significant and were not adjusted for multiple comparisons. No formal tests for interaction were conducted.
Results
There were 2018 adolescents and young adults for this analysis. Table 1 shows that participants with type 1 diabetes and those with type 2 had a distribution of characteristics similar to those of the registry population from which they came on demographic factors (average diabetes onset age, sex, and race/ distribution) and similar to those of the participants with a baseline visit on important clinical variables (hemoglobin A 1c level, BMI converted to a z score, waist circumference, waistheight ratio, and fasting C-peptide and blood pressure levels) and socioeconomic factors (insurance, household income, and parental education). Table 2 shows demographic and clinical characteristics by type of diabetes. Compared with patients with type 1 diabetes, those with type 2 were older at diagnosis (mean age, 14.2 vs 10.0 years at diagnosis) and at the outcome visit (mean age, 22.1 vs 17.9 years), with a higher proportion of female participants (66.5% vs 49.7%) and minority participants (nonHispanic black, Hispanic, American Indian, and other) (73.5% vs 24.0%). Duration of diabetes at the outcome visit was 7.9 years for both groups. Neither current nor mean hemoglobin A 1c levels were significantly different for participants with type 1 and type 2 diabetes. Measures of obesity and mean arterial pressure (current and mean over time) were significantly higher in type 2 diabetes than in type 1. A total of 72 type 2 diabetes participants (27%) did not report treatment with diabetes medications at the outcomes study visit. Table 3 shows the number of outcomes observed and the age-adjusted prevalence for each outcome at aged 21 years by type of diabetes and by both type and race/ethnicity, along with absolute differences. A higher prevalence of complications and comorbidities was observed overall among adolescents and young adults with type 2 diabetes compared with type 1, with the exception of cardiovascular autonomic neuropathy.
A total of 44 participants (19.9%) with type 2 diabetes had diabetic kidney disease compared with 89 participants (5.8%) with type 1 diabetes (absolute difference, 14.0%; 95% CI, 9.1%-19.9%; P < .001). The prevalence of diabetic retinopathy was also significantly higher for type 2 diabetes participants than for type 1 (type 2 diabetes, n = 36, 9.1%; type 1 diabetes, n = 71, 5.6%; absolute difference, 3.5%; 95% CI, 0.4%-7.7%; P = .02).
The prevalence of peripheral neuropathy was also higher in participants with type 2 diabetes vs type 1 overall (n = 58 vs 110; 17.7% vs 8.5%; absolute difference, 9.2%; 95% CI, 4.8-14.4; P < .001) and in both racial/ethnic groups. Cardiovascular autonomic neuropathy prevalence was not significantly different overall among type 2 and type 1 diabetes participants (n = 43 vs 197; 15.7% vs 14.4%; absolute difference, 1.2%; 95% CI, -3.1 to 6.5; P = .62). Because of poor model fit for race/ethnicity subsets, strata-specific comparisons of cardiovascular autonomic neuropathy prevalence by diabetes type could not be made.
Arterial stiffness prevalence was significantly higher among participants with type 2 diabetes vs those with type 1 (n = 107 vs 137; 47.4% vs 11.6%; absolute difference, 35.9%; 95% CI, 29%-42.9%; P < .001) and among both non-Hispanic whites and minority participants with type 2 diabetes compared with type 1, with an estimated prevalence of 55.4% in minority adolescents and young adults with type 2 diabetes (n = 86).
Hypertension prevalence was significantly higher in participants with type 2 diabetes vs type 1 (n = 66 vs 141; 21.6% vs 10.1%; absolute difference, 11.5%; 95% CI, 6.8%-16.9%; P < .001), including among non-Hispanic white and minority groups.
Overall, 195 teenagers and young adults with type 2 diabetes (72%) and 562 of those with type 1 diabetes (32%) had evidence of at least 1 early diabetes-related complication or comorbidity. Table 4 includes sequentially adjusted models for the associations of diabetes type and each outcome to determine whether established risk factors contributed to the higher prevalence among those with type 2 diabetes vs type 1. The base model (adjusted for age, sex, duration of diabetes, and clinical site) showed significantly higher rates of complications for type 2 diabetes vs type 1 for all outcomes, except for cardiovascular autonomic neuropathy. Adjustment for race/ ethnicity did not attenuate the higher odds of complications associated with type 2 diabetes vs type 1 for any of the outcomes explored. For diabetic kidney disease, retinopathy, and peripheral neuropathy, further adjustment for multiple risk factors did not attenuate the significantly higher odds of complications for type 2 diabetes vs type 1 prevalence, although for retinopathy, inclusion of mean arterial pressure alone attenuated the OR to nonsignificance. For arterial stiffness and hypertension, adjustment for waist-height ratio attenuated the OR to nonsignificance. With inclusion of multiple risk factors in the final model, the associations of diabetes type with arterial stiffness and hypertension were no longer significant.
Discussion
In this cohort of teenagers and young adults who had received a diagnosis of diabetes during childhood and adolescence, the prevalence of diabetes-related complications was higher among those with type 2 diabetes than with type 1, but the prevalence was substantial in both groups. At an estimated age of 21 years and after 7.9 years' mean diabetes duration, approximately 1 in 3 teenagers and young adults with type 1 diabetes (32%) and almost 3 of 4 of those with type 2 diabetes (72%) had at least 1 such complication or comorbidity, and these rates are likely to increase. Moreover, these complications dis- proportionately affected teenagers and young adults with type 2 diabetes. Participants were phenotyped to avoid misclassification by diabetes type and were followed from near onset of diabetes, with multiple risk factor measures over time and a single standardized assessment of diabetes complications and comorbidities. These results were from a US study of adolescents and young adults with youth-onset type 1 and type 2 diabetes whose data were drawn from a population-based registry. The current data, coupled with previous work, 3 suggest that the participants in this analysis are reasonably representative of the general US population with onset of type 1 and type 2 diabetes in childhood or adolescence. The microvascular complications of diabetic kidney disease, retinopathy, and peripheral neuropathy were significantly elevated among teenagers and young adults with type 2 diabetes vs those with type 1 after adjustment for glycemic control, central obesity, and blood pressure levels over time. In several studies, both diabetic kidney disease and peripheral neuropathy have been reported as elevated in individuals with youth-onset type 2 diabetes. 5, 6, [24] [25] [26] There is less consistency in regard to retinopathy, with several studies finding no significant difference in prevalence among youthonset type 2 diabetes compared with patients with type 1 diabetes. [5] [6] [7] 24, 27, 28 Two studies found a higher prevalence of retinopathy among patients with type 2 diabetes compared with those with type 1 diabetes, 25,29 as did a previous pilot study. 30 We found that the higher prevalence of retinopathy (as well as that of diabetic kidney disease) was primarily among minority adolescents and young adults with type 2 diabetes. Although it is possible that obesity played a role in the higher prevalence of retinopathy among patients with type 2 diabetes, the TODAY study found that among young persons with type 2 diabetes, retinopathy prevalence was lower among the highest tertile of obesity than among the lower tertiles.
31
In the present study, the OR for retinopathy among patients with type 2 diabetes vs type 1 remained significant when measures of obesity were added in the logistic regression models, but was attenuated and became nonsignificant when arterial pressure was included (Table 4) . These analyses suggest that mean arterial pressure may be an important factor that influenced the difference in retinopathy prevalence between type 1 and type 2 diabetes, although after inclusion of mean arterial pressure and other risk factors in the fully adjusted model, the OR indicating higher odds of retinopathy among type 2 diabetes vs type 1 remained significant. Given the young age of this group, only a small proportion received medications to control hypertension or dyslipidemia. For hypertension, this proportion was between 2% and 8%, and for dyslipidemia it was between 1% and 4%, depending on the visit. In a sensitivity analysis, the association between medication use and complications was minimal.
Because the greater association of microvascular complications in type 2 diabetes compared with type 1 remained significant after adjusting for established risk factors, these data indicate a need to explore other potential pathways, such as inflammatory markers, endothelial dysfunction, advanced glycation end products, endogenous inhibitors of nitric oxide Incidence data will be required to confirm this observation.
Whether the smaller prevalence among adolescents and young adults with type 1 diabetes, especially those of nonHispanic white background, could be related to more aggressive treatment in general must also be further explored. Comorbid outcomes included hypertension and arterial stiffness, both of which had higher prevalence among patients with type 2 diabetes and in minorities with either diabetes type. The significantly higher prevalence for both outcomes in unadjusted analyses was reduced to nonsignificance with adjustment for risk factors, primarily waist-height ratio, indicating that differences in central obesity were associated with the type 2 diabetes excess. Given that cardiovascular disease 25 and mortality 7 have been shown to be higher in young-onset type 2 diabetes than in young-onset type 1 diabetes, as well as in young-onset vs later-onset type 2 diabetes, 37 the presence of arterial stiffness and hypertension at a young age, together with an increased prevalence of risk factors 9 and diabetic kidney disease, suggests that these patients may be at increased risk for subsequent cardiovascular events. This study has several strengths. The study population was drawn from what is, to our knowledge, the largest multiethnic population-based registry of pediatric diabetes in the United States and has demographic and clinical characteristics similar to those of the overall population from which it draws. 3 Even though the outcomes were based on crosssectional assessment, risk factors were measured longitudinally at previous visits, allowing the determination of the relationship of glucose control, markers of overall and central obesity, and mean blood pressure levels over time with differences in the prevalence of complications by diabetes type. This study also has some limitations. First, a single measure of each outcome was used, without repeated testing. Second, there were relatively small numbers of participants with some outcomes, especially in subgroups by race/ ethnicity. Third, the analysis of risk factors that might explain differences by type of diabetes did not include all possible factors and pathways. Fourth, it is possible that participants with youth-onset type 2 diabetes had a longer period of undetected glycemia such that the duration of hyperglycemia was longer than for type 1 diabetes. Data are not available in this study to address this question; however, surveys of highrisk minority youths have identified few with undiagnosed type 2 diabetes in cross-sectional surveys of glucose intolerance.
38,39 If youth-onset type 2 diabetes had a longer preclinical course, it would be expected that a larger number of such undiagnosed cases would be identified. Fourth, the mean number of measures of risk factors was 3.2 for patients with type 1 diabetes and 3.0 for those with type 2 diabetes, so it is possible that the true excursions of hemoglobin A 1c level and blood pressure were underestimated. This could have led to less ability to fully characterize the associations of hemoglobin A 1c level and blood pressure with complications according to type of diabetes. Fifth, there were a large number of end points compared, without adjustment for multiple comparisons, so it is possible that some of the statistically significant findings represent type I error.
Conclusions
Among teenagers and young adults who had been diagnosed with diabetes during childhood and adolescence, the prevalence of complications and comorbidities was higher among those with type 2 diabetes compared with type 1, but frequent in both groups. These findings support early monitoring of these patients for development of complications.
